Inclusive of all taxes
MYTERA 500 MG (Abiraterone Acetate Tablets) is a potent pharmaceutical formulation specifically designed for the treatment of advanced prostate cancer. Each tablet contains 500 mg of Abiraterone Acetate, a selective inhibitor of the CYP17 enzyme, which is critical in androgen biosynthesis. By inhibiting CYP17, MYTERA effectively reduces androgen production in testes, adrenal glands, and prostate tumor tissue, helping to manage hormone-sensitive and castration-resistant prostate cancer. This medication is intended for prescription use under the supervision of oncologists and healthcare professionals and is commonly employed in combination with prednisone to enhance therapeutic outcomes. MYTERA offers sustained release and optimal bioavailability to ensure consistent plasma concentrations for effective cancer control. Suitable for administration in adult male patients with metastatic castration-resistant prostate cancer, MYTERA 500 MG is an essential part of targeted hormone therapy protocols.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Abiraterone Acetate 500 mg per tablet |
| Therapeutic Use | Treatment of metastatic castration-resistant prostate cancer |
| Mechanism of Action | Selective CYP17 enzyme inhibitor reducing androgen production |
| Dosage Form | Oral Tablets |
| Administration Route | Oral |
| Packaging | Blister pack of 30 tablets |
| Intended Patient Group | Adult male patients with prostate cancer |
| Combination Therapy | Used alongside prednisone as per treatment guidelines |
| Manufacturer | Reputed Pharmaceutical Company |
| Attributes | Description |
|---|---|
| Tablet Strength | 500 mg |
| Composition | Abiraterone Acetate, Excipients |
| Pharmacological Class | Androgen biosynthesis inhibitor |
| Shelf Life | 24 months from manufacturing date |
| Storage Conditions | Store below 25°C, protect from moisture and light |
| Regulatory Approval | Approved by CDSCO (India) and other relevant authorities |
| Prescription Status | Prescription Only Medicine (POM) |
| Tablet Appearance | Round, film-coated, white to off-white tablets |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
MYTERA 500 MG is specifically approved and recommended for metastatic castration-resistant prostate cancer and hormone-sensitive prostate cancer under specific conditions, but may not be suitable for early-stage prostate cancer.
MYTERA is generally prescribed in combination with low-dose prednisone to mitigate side effects; use without prednisone should only be under strict medical supervision.
Store MYTERA tablets below 25°C in a dry place, protected from moisture and light to maintain efficacy.
Yes, MYTERA 500 MG is available for bulk orders suitable for hospital pharmacies and cancer treatment centers.
Yes, MYTERA 500 MG requires CDSCO approval and is a prescription-only medication compliant with Indian pharmaceutical regulations.
Country Of Origin: India
Inclusive of all taxes
You Save: 0
